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The impact of reverse genetics, synthetic biology, and gene
therapy has been restricted by the limitations of conven-
tional genetic engineering technologies. To expand the
capacity for genetic modification of mammalian cells, we
are engineering artificial DNA-binding proteins, including
zinc finger proteins, TAL effectors, and CRISPR/Cas9 to
regulate and edit endogenous mammalian genes. For exam-
ple, we have engineered both protein-based and RNA-
guided transcriptional activators and repressors targeted to
human genes relevant to medicine, science, and biotechnol-
ogy. Delivery of combinations of transcription factors led to
synergistic effects on gene activation and tunable expres-
sion levels. This approach recapitulates the previously
intractable complexity of natural regulation of mammalian
genes that is the product of cooperative actions of many
transcription factors. We have also developed novel meth-
ods for controlling the activity of these proteins, such as
optogenetic regulation of protein dimerization with blue
light. Genome-wide analysis of the DNA-binding, gene reg-
ulation, and chromatin remodeling of these targeted epi-
genome modifiers has demonstrated their exceptional
specificity. In other studies we have engineered synthetic
nucleases to stimulate gene targeting to genomic safe har-
bor sites. This approach is particularly useful for generating
isogenic cell lines. We showed that this method leads to a
decrease in the variability of transgene expression within a
clonal cell line and between multiple clones relative to con-
ventional techniques. Finally, we have used similar methods
to correct mutations causing genetic disease. We engi-
neered synthetic nucleases targeted to the human dystro-
phin gene that is mutated in Duchenne muscular dystrophy
patients. When we delivered these nucleases to cells from
patients with this disease, the correct gene reading frame
and expression of the functional dystrophin protein were
restored in vitro and following cell transplantation in vivo.
We further demonstrated that these nucleases were well-
tolerated and did not lead to off-target alterations of the
exome in several corrected clonal cell populations. Collec-
tively, these studies demonstrate the potential of engineered
DNA-binding proteins to enable new approaches in medi-
cine, science, and technology.
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